These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 16797681)

  • 1. The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.
    Numnum TM; Rocconi RP; Whitworth J; Barnes MN
    Gynecol Oncol; 2006 Sep; 102(3):425-8. PubMed ID: 16797681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer.
    Hamilton CA; Maxwell GL; Chernofsky MR; Bernstein SA; Farley JH; Rose GS
    Gynecol Oncol; 2008 Dec; 111(3):530-2. PubMed ID: 18561992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screening.
    Simpkins F; Belinson JL; Rose PG
    Gynecol Oncol; 2007 Oct; 107(1):118-23. PubMed ID: 17658587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites?
    Kobold S; Hegewisch-Becker S; Oechsle K; Jordan K; Bokemeyer C; Atanackovic D
    Oncologist; 2009 Dec; 14(12):1242-51. PubMed ID: 20008305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The usefulness of bevacizumab for relief from symptomatic malignant ascites in patients with heavily treated recurrent ovarian cancer.
    Shimizu Y; Kajiyama H; Yoshida K; Tamauchi S; Nakanishi T; Kikkawa F
    J Obstet Gynaecol Res; 2019 Dec; 45(12):2435-2439. PubMed ID: 31468618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The use of bevacizumab in refractory peritoneal dissemination of gastric cancer with malignant ascites-two case reports].
    Kinoshita J; Fushida S; Makino I; Nakamura K; Oyama K; Nakagawara H; Fujita H; Tajima H; Takamura H; Ninomiya I; Kitagawa H; Tani T; Miyamoto M; Fujimura T; Ota T
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2360-2. PubMed ID: 22202382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer.
    Cohn DE; Valmadre S; Resnick KE; Eaton LA; Copeland LJ; Fowler JM
    Gynecol Oncol; 2006 Aug; 102(2):134-9. PubMed ID: 16527339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of bevacizumab in refractory ovarian granulosa-cell carcinoma with symptomatic relief of ascites: a case report.
    Kesterson JP; Mhawech-Fauceglia P; Lele S
    Gynecol Oncol; 2008 Dec; 111(3):527-9. PubMed ID: 18710781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab in heavily pre-treated and platinum resistant ovarian cancer: a retrospective study of the North-Eastern German Society of Gynaecologic Oncology (NOGGO) Ovarian Cancer Study Group.
    Pietzner K; Richter R; Chekerov R; Erol E; Oskay-Özcelik G; Lichtenegger W; Sehouli J
    Anticancer Res; 2011 Aug; 31(8):2679-82. PubMed ID: 21778323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab.
    Smerdel MP; Steffensen KD; Waldstrøm M; Brandslund I; Jakobsen A
    Gynecol Oncol; 2010 Aug; 118(2):167-71. PubMed ID: 20471067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.
    Cannistra SA; Matulonis UA; Penson RT; Hambleton J; Dupont J; Mackey H; Douglas J; Burger RA; Armstrong D; Wenham R; McGuire W
    J Clin Oncol; 2007 Nov; 25(33):5180-6. PubMed ID: 18024865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer.
    de Gramont A; Van Cutsem E
    Oncology; 2005; 69 Suppl 3():46-56. PubMed ID: 16301835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
    Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
    Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab in the treatment of ovarian cancer.
    Heitz F; Harter P; Barinoff J; Beutel B; Kannisto P; Grabowski JP; Heitz J; Kurzeder C; du Bois A
    Adv Ther; 2012 Sep; 29(9):723-35. PubMed ID: 22941523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of malignant ascites after intraperitoneal chemotherapy in women with carcinoma of the ovary.
    Lind SE; Cashavelly B; Fuller AF
    Surg Gynecol Obstet; 1988 Jun; 166(6):519-22. PubMed ID: 3375962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal pressures and clinical parameters of total paracentesis for palliation of symptomatic ascites in ovarian cancer.
    Gotlieb WH; Feldman B; Feldman-Moran O; Zmira N; Kreizer D; Segal Y; Elran E; Ben-Baruch G
    Gynecol Oncol; 1998 Dec; 71(3):381-5. PubMed ID: 9887235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.
    Chamberlain MC; Johnston S
    Cancer; 2009 Apr; 115(8):1734-43. PubMed ID: 19197992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
    Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
    Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.